Burkitt Lymphoma/Leukemia Presented on 68Ga-Pentixafor and 18F-FDG PET/CT. (January 2022)

• Record Type: Journal Article
• Authors: Chen, Zhenying; Xue, Qianqian; Huang, Chao; Yao, Shaobo; Miao, Weibing
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 1(2022)
• Publication Date: 2022-01
• Subjects: 68Ga-Pentixafor -- Burkitt lymphoma/leukemia -- 18F-FDG -- PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003750
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: An 18-year-old man with newly diagnosed Burkitt lymphoma/leukemia was referred for 18 F-FDG and 68 Ga-Pentixafor PET/CT. 68 Ga-Pentixafor PET/CT revealed similar radioactivity uptake pattern to the 18 F-FDG PET/CT in superior phrenic lymph node, ascending colon, ileocecum, peritoneal, marrow, and spleen. This case highlighted that it might be interesting to further investigate the role of 68 Ga-Pentixafor PET/CT imaging in staging, treatment evaluation, and especially the feasibility of CXCR4-directed radioligand therapy in Burkitt lymphoma with positive expression of CXCR4.